Trial
NCT03580382
Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
NYU Langone Health
Collaborators
Celldex Therapeutics
Condition
Melanoma
Intervention
Trametinib daily Until PD
Why stopped
Per regulatory coordinator, the sponsor is no longer supporting the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-05-20